Life sciences hubs beyond Boston and the Bay Area are giving startups new opportunities to grow and scale their businesses, ...

Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

Predicting how cells behave in a bioreactor is one of the more demanding challenges in biologics manufacturing. Classical data-driven models offer a practical starting point, but they rely on fitting ...

Regulatory submissions are entering a period of meaningful structural change. eCTD 4.0 is gaining traction at both the FDA and EMA, offering practical improvements over its predecessor: more flexible ...

SK pharmteco’s ADC payload and linker solutions integrate scale, safety, and deep scientific expertise to support even the most technically demanding programs. Our right-sized, purpose-built ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...